Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03808155
Other study ID # GR20192021
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date August 1, 2019
Est. completion date June 30, 2024

Study information

Verified date March 2023
Source Kantonsspital Graubünden
Contact Räto T. Strebel, PD Dr. med.
Phone +41 81 256 62 35
Email raeto.strebel@ksgr.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Various studies have shown that the risk of suffering a urinary retention after knee or hip prosthesis surgery is 10-80%. The aim of the study is to reduce this riks. For this purpose, it is investigated whether a previously known drug (tamsulosin) which is used in bladder emptying disorders, can achieve a reduction in urinary retention after surgery. After the patients agree to participate in the study, they are examined in our urological clinic. Uroflowmetry is performed with sonographic residual volume measurement and prostate volume measurement. Furthermore, a standardized Voiding questionaire (IPSS) is completed. This study is conducted as a double-blind study using a placebo control group. The drug / placebo is taken once a day, five days before and two days after surgery. Subsequently, it is observed whether it comes to a urinary retention or not. After the operation, no further urological checks are planned or needed.


Description:

Study Category and rationale: This study uses a well-known drug (tamsulosin) which is authorised in Switzerland and widely used to treat obstructive voiding problems. In our case the indication is different from that specified in the prescribing information, but it is within the same disease group, which in our case is to prevent urinary retention. Therefore according to the legal ordinance on clinical trials (ClinO), this study is classified as a clinical trial, research with collection of health-related personal data and placebo controlled of the category B. Objective: Our goal is to reduce the rate of postoperative urinary retention after lower limb arthroplasty. For this purpose, we plan to investigate whether an already known drug (Tamsulosin), which is widely used for bladder emptying disorders, could reduce the rate of postoperative urinary retention. Outcomes: The primary outcome is the occurrence of urinary retention during the 48 postoperative hours. The secondary outcome is the influence of other clinical factors on the occurrence of urinary retention as type of anaesthesia, preoperative residual volume, prostate size and international prostate symptom score (IPSS). Measurement and procedures: Once the decision for lower limb arthroplasty is made during the planned orthopaedic consultation, the patient will receive a participant information sheet and the informed consent. If the patient is interested to take part in the study he will receive an appointment in the urological clinic at least six days before the operation. During the appointment a urological specialist will explain the entire study. A uroflowmetry with sonographic measurement of residual volume and prostate volume will be performed. Furthermore, the patient will fill out an IPSS-questionnaire. After the appointment the drug/placebo will be handed out to the patient, which should be taken once a day five days prior to the operation, on the day of surgery and two days thereafter. Study product: The study specific product Tamsulosin 0.4mg, a tablet which is taken once a day per os five days prior to the operation and two days after the operation. Control intervention: Placebo. Number of participants with rationale: The number of participants projected for the entire study is 170. Thus 85 patients in the drug-treatment group and 85 patients for the placebo-treatment group.


Recruitment information / eligibility

Status Recruiting
Enrollment 170
Est. completion date June 30, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - male adults undergoing elective hip- or knee arthroplasty Exclusion Criteria: - women - underage patients - pre-existing treatment with tamsulosin or other prostate affecting medication - patients who underwent transurethral resection of the prostate or prostatectomy - patients with urethral strictures - patients with neurological bladder dysfunction - Known allergy to tamsulosin - Hypotensive disorder

Study Design


Intervention

Drug:
Tamsulosin
The drug ist taken once a day per os five days prior to the operation and two days after the operation.
Placebo Oral Tablet
The placebo ist taken once a day per os five days prior to the operation and two days after the operation.

Locations

Country Name City State
Switzerland Kantonsspital Graubünden Chur Graubünden

Sponsors (1)

Lead Sponsor Collaborator
Kantonsspital Graubünden

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of urinary retention The primary outcome is the occurrence of urinary retention during the 48 postoperative hours. 48 hours postoperatively
Secondary Type of anaesthesia Did the patient undergo general anaesthesia, spinal anaesthesia or regional anaesthesia 48 hours postoperatively
Secondary Preoperative residual volume Preoperatively the residual volume will be measured in milliliters (mL) by ultrasound. Minimum 6 days before the planned operation.
Secondary Prostate size Preoperatively the prostate volume will be measured in milliliters (mL) by ultrasound. Minimum 6 days before the planned operation.
Secondary International prostate symptom score (IPSS). The International Prostate Symptom Score (I-PSS) is based on the answers to seven questions concerning urinary symptoms and one question concerning quality of life. Each question concerning urinary symptoms allows the patient to choose one out of six answers indicating increasing severity of the particular symptom. The answers are assigned points from 0 to 5. The total score can therefore range from 0 to 35 (asymptomatic to very symptomatic). Minimum 6 days before the planned operation.
See also
  Status Clinical Trial Phase
Terminated NCT03940651 - Cardiac and Renal Biomarkers in Arthroplasty Surgery Phase 4
Completed NCT05593341 - Opioid Education in Total Knee Arthroplasty N/A
Not yet recruiting NCT05290818 - Total Versus Robotic Assisted Unicompartmental Knee Replacement N/A
Withdrawn NCT04099355 - Investigating the Effect of Dronabinol on Post-surgical Pain Early Phase 1
Recruiting NCT04924205 - A Comparison Of Primary TKA Rehabilitation Using A Smart Orthotic Versus Outpatient Physical Therapy N/A
Completed NCT05399043 - Experience of Use and Biopsychosocial Effects of Robotic and Virtual Reality Devices in Neuromotor Rehabilitation N/A
Terminated NCT03185117 - Opioid Consumption After Hospital Discharge in Orthopedic Surgery
Completed NCT04118023 - 7T MRI to Evaluate Cartilage Defects in the Knee
Terminated NCT03260699 - Economic and Functional Impact of Peri-Operative Bracing for Primary Total Knee Arthroplasty (TKA) N/A
Recruiting NCT03283878 - Antibiotic Prophylaxis in Patients Undergoing Elective TKA- Multi-center Trial Phase 4
Completed NCT03133481 - Adductor Canal Block Versus Femoral Nerve Block for Total Knee Arthroplasty Phase 3
Active, not recruiting NCT04684160 - Comparison of Joint Awareness Between Fixed-bearing and Mobile-bearing Total Knee Arthroplasty Using Titanium-nitride Coated Posterior-stabilized Prostheses N/A
Completed NCT03282201 - A Survey on Blood Transfusions in Major Artrhoplasty Operations
Recruiting NCT06259032 - Comparative Effect of Mechanical and Functional Alignment in Bilateral Total Knee Arthroplasty on Ankle Alignment N/A
Completed NCT02928562 - The Impaction of Exercise Training on Bone Mineral Density in Patients After Total Knee Arthroplasty N/A
Completed NCT04481711 - Total Knee Arthroplasty and Clinical Findings N/A
Recruiting NCT01135160 - Evaluation of Weight Bearing After Total Hip and Knee Replacement
Completed NCT03921034 - IPACK Nerve Block for Total Knee Arthroplasty Phase 4
Active, not recruiting NCT05248815 - Muscle Strength and Total Knee Replacement
Not yet recruiting NCT06024161 - Weight Change and the Risk of Chronic Pain Following Hip and Knee Arthroplasties